drugset / Trial / NCT05340621
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
NaSequentialOpen-labelTreatment
Summary
The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2025-01-29
- Completion
- 2025-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BOCODEPSIN | Small molecule | — | Oral |
| Subject | Binimetinib | Small molecule | — | Oral |